Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Aclaris Therapeutics (ACRS) has provided an update.
Aclaris Therapeutics has struck a lucrative deal with OMERS, selling a portion of its future royalty payments and associated milestones from its license with Eli Lilly for OLUMIANT, a treatment for alopecia areata. The transaction nets Aclaris an immediate $26.5 million, with the potential for an additional $5 million, depending on sales achievements in 2024. OMERS, in return, gains a slice of the ongoing royalty pie from global sales of OLUMIANT, reinforcing its investment portfolio in the healthcare sector. This strategic financial move was also publicized through a press release to keep investors informed.
For an in-depth examination of ACRS stock, go to TipRanks’ Stock Analysis page.
